| Dr Jennifer Oboza Heller, MD | |
|
9 Flowers Dr, Mechanicsburg, PA 17050-1701 | |
| (717) 691-8750 | |
| (717) 691-8755 |
| Full Name | Dr Jennifer Oboza Heller |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 37 Years |
| Location | 9 Flowers Dr, Mechanicsburg, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164652442 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | MD437933 (Pennsylvania) | Primary |
| 207V00000X | Obstetrics & Gynecology | 254058 (New York) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Pinnacle Health Hospitals | Harrisburg, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Pinnacle Health Medical Services | 7618960493 | 942 |
News Archive
In a series of experiments with mice, Johns Hopkins investigators have used an experimental compound to successfully reverse hair loss, hair whitening and skin inflammation linked by previous studies to human diets heavy in fat and cholesterol.
Spectral Diagnostics Inc. and BioMS Medical Corp. today announced that BioMS Medical ("BioMS") and a syndicate of investors have invested $14 million in Spectral Diagnostics ("Spectral", or the "Company") to advance Toraymyxin(TM), a treatment for severe sepsis, towards regulatory approval and commercialization in the United States.
A University of Adelaide researcher has published results that suggest a possible new mechanism to control multiple sclerosis (MS).
UCSF researchers have developed a new approach to identify specific genes that influence how cancer cells respond to drugs and how they become resistant. This strategy, which involves producing diverse genetic mutations that result in leukemia and associating specific mutations with treatment outcomes, will enable researchers to better understand how drug resistance occurs in leukemia and other cancers, and has important long-term implications for the development of more effective therapies.
› Verified 8 days ago
| Entity Name | Pinnacle Health Medical Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932143427 PECOS PAC ID: 7618960493 Enrollment ID: O20040407000180 |
News Archive
In a series of experiments with mice, Johns Hopkins investigators have used an experimental compound to successfully reverse hair loss, hair whitening and skin inflammation linked by previous studies to human diets heavy in fat and cholesterol.
Spectral Diagnostics Inc. and BioMS Medical Corp. today announced that BioMS Medical ("BioMS") and a syndicate of investors have invested $14 million in Spectral Diagnostics ("Spectral", or the "Company") to advance Toraymyxin(TM), a treatment for severe sepsis, towards regulatory approval and commercialization in the United States.
A University of Adelaide researcher has published results that suggest a possible new mechanism to control multiple sclerosis (MS).
UCSF researchers have developed a new approach to identify specific genes that influence how cancer cells respond to drugs and how they become resistant. This strategy, which involves producing diverse genetic mutations that result in leukemia and associating specific mutations with treatment outcomes, will enable researchers to better understand how drug resistance occurs in leukemia and other cancers, and has important long-term implications for the development of more effective therapies.
› Verified 8 days ago
| Entity Name | Cumberland Valley Obstetrics & Gynecology, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881626653 PECOS PAC ID: 8325085186 Enrollment ID: O20050413000329 |
News Archive
In a series of experiments with mice, Johns Hopkins investigators have used an experimental compound to successfully reverse hair loss, hair whitening and skin inflammation linked by previous studies to human diets heavy in fat and cholesterol.
Spectral Diagnostics Inc. and BioMS Medical Corp. today announced that BioMS Medical ("BioMS") and a syndicate of investors have invested $14 million in Spectral Diagnostics ("Spectral", or the "Company") to advance Toraymyxin(TM), a treatment for severe sepsis, towards regulatory approval and commercialization in the United States.
A University of Adelaide researcher has published results that suggest a possible new mechanism to control multiple sclerosis (MS).
UCSF researchers have developed a new approach to identify specific genes that influence how cancer cells respond to drugs and how they become resistant. This strategy, which involves producing diverse genetic mutations that result in leukemia and associating specific mutations with treatment outcomes, will enable researchers to better understand how drug resistance occurs in leukemia and other cancers, and has important long-term implications for the development of more effective therapies.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jennifer Oboza Heller, MD 9 Flowers Dr, Mechanicsburg, PA 17050-1701 Ph: (717) 691-8750 | Dr Jennifer Oboza Heller, MD 9 Flowers Dr, Mechanicsburg, PA 17050-1701 Ph: (717) 691-8750 |
News Archive
In a series of experiments with mice, Johns Hopkins investigators have used an experimental compound to successfully reverse hair loss, hair whitening and skin inflammation linked by previous studies to human diets heavy in fat and cholesterol.
Spectral Diagnostics Inc. and BioMS Medical Corp. today announced that BioMS Medical ("BioMS") and a syndicate of investors have invested $14 million in Spectral Diagnostics ("Spectral", or the "Company") to advance Toraymyxin(TM), a treatment for severe sepsis, towards regulatory approval and commercialization in the United States.
A University of Adelaide researcher has published results that suggest a possible new mechanism to control multiple sclerosis (MS).
UCSF researchers have developed a new approach to identify specific genes that influence how cancer cells respond to drugs and how they become resistant. This strategy, which involves producing diverse genetic mutations that result in leukemia and associating specific mutations with treatment outcomes, will enable researchers to better understand how drug resistance occurs in leukemia and other cancers, and has important long-term implications for the development of more effective therapies.
› Verified 8 days ago
Dr. Robert W Bucher Jr., M.D., Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 9 Flowers Dr, Mechanicsburg, PA 17050 Phone: 717-691-8750 Fax: 717-691-8755 | |
Dr. Sharon Ann-romano Fitzgerald, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2035 Technology Pkwy Ste 201, Mechanicsburg, PA 17050 Phone: 717-221-5940 Fax: 717-233-1939 | |
Dr. Mark Andrew Miller, DO Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2035 Technology Pkwy Ste 201, Mechanicsburg, PA 17050 Phone: 717-221-5940 Fax: 717-233-1939 | |
Timothy Deimling, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2025 Technology Pkwy Ste 108, Mechanicsburg, PA 17050 Phone: 717-988-8170 Fax: 717-221-5398 | |
Andrea Benton, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2025 Technology Pkwy Ste 108, Mechanicsburg, PA 17050 Phone: 717-988-8170 Fax: 717-221-5398 | |
Dr. Khanh-ha Dan Nguyen, M.D., MPH Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 2025 Technology Pkwy, Suite 211, Mechanicsburg, PA 17050 Phone: 717-516-1620 Fax: 717-516-1621 |